Novel tuberculosis combination regimens of two and three-months therapy duration
Gumbo, T.; Chapagain, M.; Magombedze, G.; Srivastava, S.; Deshpande, D.; Pasipanodya, J. G.; Gumbo, R.; Dheda, K.; Diacon, A.; Hermann, D. J.; Hanna, D.
Show abstract
The tuberculosis treatment duration is 4-6 months, but can be 18-20 months with multidrug resistance. Ultrashort regimens that cure regardless of resistance status ["pan-tuberculosis regimens"] would be a major step towards global tuberculosis control. Starting with seven drugs [bedaquiline, delamanid, pretomanid, OPC-167832, sutezolid, moxifloxacin, and pyrazinamide] in clinical testing, we calculated that there were thousands of possible novel combinations to evaluate. We used mathematical and pharmacokinetics/pharmacodynamic-based hollow fiber modeling to reduce this complexity to nine combinations, which we tested. Each regimens fast and slow growth bacteria kill-slope trajectories and times-to-extinction were estimated and translated to minimum required therapy duration in patients. Sputum microbial kill trajectories of two combination regimens that have undergone clinical testing were correctly predicted by this approach. Four pan-tuberculosis regimens were predicted to achieve relapse-free cure after 2-3 months therapy in patients. The kill-slopes were used to design expedited clinical trials that minimize patients risks.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- An antifungal with a novel mechanism of action discovered via resistance gene-guided genome mining 91%
- A chemiluminescent protease probe for rapid, sensitive, and inexpensive detection of live Mycobacterium tuberculosis 90%
- A High-Throughput Screen Reveals the Structure-Activity Relationship of the Antimicrobial Lasso Peptide Ubonodin 90%
Similar papers in this journal
- Using dynamic oral dosing of rifapentine and rifabutin to simulate exposure profiles of long-acting formulations in a mouse model of tuberculosis preventive therapy 94%
- Sulbactam-Durlobactam Plus Ceftriaxone Dosing and Novel Treatment Regimens for Mycobacterium abscessus Lung Disease 93%
- Contribution of front-line, standard of care drugs to bactericidal responses, resistance emergence, and cure in murine models of easy- or hard-to-treat tuberculosis disease 93%
Similar papers in this journal
- A multiplexed, target-based phenotypic screening platform using CRISPR interference in Mycobacterium abscessus 93%
- An engineered prodrug selectively suppresses β-lactam resistant bacteria in a mixed microbial setting 93%
- Tre-DST: A new drug susceptibility test for Mycobacterium tuberculosis using solvatochromic trehalose probes 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.